DelveInsight’s “Familial Hypercholesterolemia Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Familial Hypercholesterolemia pipeline landscape. It covers the Familial Hypercholesterolemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Familial Hypercholesterolemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Familial Hypercholesterolemia Pipeline. Dive into DelveInsight's comprehensive report today! @ Familial Hypercholesterolemia Pipeline Outlook
Key Takeaways from the Familial Hypercholesterolemia Pipeline Report
- On 27 August 2025, Amryt Pharma conducted a study is designed to determine if lomitapide is effective and can be safely administered to paediatric patients with HoFH. If the efficacy and safety so far observed in adults is confirmed in paediatric patients, the potential exists to significantly lower low-density lipoprotein cholesterol (LDL-C) levels in paediatric patients with HoFH. Furthermore, the lower LDL-C levels may reduce atherosclerosis progression and would be expected to benefit these paediatric patients with HoFH.
- DelveInsight’s Familial Hypercholesterolemia Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Familial Hypercholesterolemia treatment.
- The leading Familial Hypercholesterolemia Companies such as Akeso Biopharma, Innovent Biologics, Jiangsu Hengrui Medicine, LIB Therapeutics, Arrowhead Pharmaceuticals, Precision BioSciences, Verve Therapeutics, SalioGen Therapeutics and others.
- Promising Familial Hypercholesterolemia Therapies such as Rosuvastatin Calcium, JTT-705 300mg, DRL-1782, AZD0780, Enlicitide Decanoate, Lomitapide, and others.
Get insights into Familial Hypercholesterolemia Clinical Trials, emerging therapies, and leading companies with DelveInsight @ Familial Hypercholesterolemia Treatment Drugs
Familial Hypercholesterolemia Emerging Drugs Profile
- Ebronucimab: Akeso Biopharma
Ebronucimab (AK-102) is a monoclonal antibody based therapy targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Ebronucimab is being developed for the treatment of primary hyperlipidemias, including homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH) and other primary hypercholesterolemia patients.
- Tafolecimab: Innovent Biologics
Tafolecimab (IBI306) is fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9. The drug is currently in Phase III clinical trials for patients with homozygous or heterozygous familial hypercholesterolemia. PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver’s ability to remove LDL-C, or “bad” cholesterol, from the blood.
The Familial Hypercholesterolemia Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Familial Hypercholesterolemia with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Familial Hypercholesterolemia Treatment.
- Familial Hypercholesterolemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Familial Hypercholesterolemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Familial Hypercholesterolemia market
Explore groundbreaking therapies and clinical trials in the Familial Hypercholesterolemia Pipeline. Access DelveInsight's detailed report now! @ New Familial Hypercholesterolemia Drugs
Familial Hypercholesterolemia Companies
Akeso Biopharma, Innovent Biologics, Jiangsu Hengrui Medicine, LIB Therapeutics, Arrowhead Pharmaceuticals, Precision BioSciences, Verve Therapeutics, SalioGen Therapeutics and others.
Familial Hypercholesterolemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Learn about new Familial Hypercholesterolemia drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Familial Hypercholesterolemia Market Drivers and Barriers
Scope of the Familial Hypercholesterolemia Pipeline Report
- Coverage- Global
- Familial Hypercholesterolemia Companies- Akeso Biopharma, Innovent Biologics, Jiangsu Hengrui Medicine, LIB Therapeutics, Arrowhead Pharmaceuticals, Precision BioSciences, Verve Therapeutics, SalioGen Therapeutics and others.
- Familial Hypercholesterolemia Therapies- Rosuvastatin Calcium, JTT-705 300mg, DRL-1782, AZD0780, Enlicitide Decanoate, Lomitapide, and others.
- Familial Hypercholesterolemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Familial Hypercholesterolemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight's in-depth Familial Hypercholesterolemia Pipeline report today! @ Familial Hypercholesterolemia Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Familial Hypercholesterolemia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Familial Hypercholesterolemia – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Familial Hypercholesterolemia Collaboration Deals
- Late Stage Products (Phase III)
- Tafolecimab: Innovent Biologics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Ebronucimab: Akeso Biopharma
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ARO-ANG3: Arrowhead Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- VERVE-101: Verve Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Familial Hypercholesterolemia Key Companies
- Familial Hypercholesterolemia Key Products
- Familial Hypercholesterolemia- Unmet Needs
- Familial Hypercholesterolemia- Market Drivers and Barriers
- Familial Hypercholesterolemia- Future Perspectives and Conclusion
- Familial Hypercholesterolemia Analyst Views
- Familial Hypercholesterolemia Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-hypercholesterolemia-pipeline-insight
